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Abstract
Background: This study was aimed at evaluating the clinical protection, the level of Porcine circovirus type 2
(PCV2) viremia and the immune response (antibodies and IFN-γ secreting cells (SC)) in piglets derived from PCV2
vaccinated sows and themselves vaccinated against PCV2 at different age, namely at 4, 6 and 8 weeks. The cohort
study has been carried out over three subsequent production cycles (replicates). At the start/enrolment, 46 gilts
were considered at first mating, bled and vaccinated. At the first, second and third farrowing, dams were bled
and re-vaccinated at the subsequent mating after weaning piglets. Overall 400 piglets at each farrowing (first,
second and third) were randomly allocated in three different groups (100 piglets/group) based on the timing of
vaccination (4, 6 or 8 weeks of age). A fourth group was kept non-vaccinated (controls). Piglets were vaccinated
intramuscularly with one dose (2 mL) of a commercial PCV2a-based subunit vaccine (Porcilis® PCV). Twenty animals
per group were bled at weaning and from vaccination to slaughter every 4 weeks for the detection of PCV2
viremia, humoral and cell-mediated immune responses. Clinical signs and individual treatments (morbidity),
mortality, and body weight of all piglets were recorded.
Results: All vaccination schemes (4, 6 and 8 weeks of age) were able to induce an antibody response and IFN-γ SC.
The highest clinical and virological protection sustained by immune reactivity was observed in pigs vaccinated
at 6 weeks of age. Overall, repeated PCV2 vaccination in sows at mating and the subsequent higher levels of
maternally derived antibodies did not significantly interfere with the induction of both humoral and cell-mediated
immunity in their piglets after vaccination.
Conclusions: The combination of vaccination in sows at mating and in piglets at 6 weeks of age was more
effective for controlling PCV2 natural infection, than other vaccination schemas, thus sustaining that some
interference of MDA with the induction of an efficient immune response could be considered. In conclusion,
optimal vaccination strategy needs to balance the levels of passive immunity, the management practices and
timing of infection.
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Background
The control of Porcine circovirus type 2 (PCV2) associ-
ated diseases (PCVD) is based on management strat-
egies, control of coinfections, and vaccination. At
present, different commercial PCV2 vaccines are avail-
able, licenced for use in piglets most often from three
weeks of age and all of them have been described to be
effective in controlling the disease [4, 6, 9, 15, 29]. In
fact, the PCV2 vaccines are able to reduce the viral bur-
den and viral-induced specific lesions in the lymphoid
tissue, but the potential interference of vaccines with
maternally derived immunity and the optimization of
the vaccination timing are still worth investigating. Dee-
per understanding is required with regard to the age-
related maturity and responsiveness of piglets’ immune
system towards PCV2 vaccines and the extent of passive
immunity either from sows’ PCV2 infection or vaccin-
ation. Several studies showed that vaccination against
PCV2 in piglets with high levels of maternally derived
antibodies (MDA) can result in clinical protection [4, 9,
14, 15, 22]. However, in some of these studies, maternal
immunity apparently interfered with the humoral im-
mune response after vaccination [9, 22]. Most of the
authors characterised the humoral immunity towards
PCV2 by determination of total PCV2-specific anti-
bodies and/or by demonstration of an increase of the
concentration showing seroconversion that occurs either
in subclinically infected or clinically affected pigs, e.g.
PMWS-affected pigs [10, 26, 30]. Apart from the
humoral immunity, previous reports based on laboratory
trials demonstrated that cell-mediated immunity mea-
sured as levels of PCV2-specific interferon-γ (IFN-γ) se-
creting cells (SC) may play a role in mediating viral
clearance in combination with neutralising antibodies
and that the intensity of the cell-mediated immune
response may be influenced by the load and the extent
of viral replication [7, 18, 19]. These features were
investigated under field conditions both in diseased pigs
naturally infected with PCV2 in combination with coin-
fections and in vaccinated animals showing no or only a
few clinical signs [5, 16, 23, 31].
Previous studies showed that high levels of MDA in
piglets do not allow eliciting seroconversion after vaccin-
ation. Conversely, when the level of passively acquired
antibodies is lower than a certain titre (exact value is de-
pending on the serological method), the vaccine admin-
istration induces a marked seroconversion [8, 9, 15, 16].
Usually, in piglets vaccinated in the face of a high level
of passive immunity, a decline of antibody is observed
similarly to the decline in unvaccinated animals. More-
over, Haake and others [11] suggested that vaccination
at one week of age clearly affects the induction of an
active humoral immunity in piglets. In contrast, the
cell-mediated immune response is not affected by
MDA levels and contributes to the long-lasting pro-
tection [5, 7, 8, 15].
This study was aimed at investigating the clinical pro-
tection (vaccine efficacy) and the immune responses
(both humoral and cell-mediated) of a one-dose PCV2
subunit vaccine administered in piglets. In particular,
identifying the ideal time of vaccination (4, 6 or 8 weeks
of age), also in respect to their levels of passively ac-
quired immunity being derived from gilts and sows re-
peatedly vaccinated at mating against the same antigen,
was of interest. The outcome parameters were com-
prised by clinical (morbidity and mortality), productive
(average daily weight gain - ADWG), and virological
(PCV2 viremia and viral load) parameters. The immune
response in piglets was assessed in terms of development
of humoral (total antibodies) and cell-mediated (PCV2-
specific IFN-γ secreting cells) immunity.
Methods
Clinical history of the herd
The study was carried out in the Northern part of Italy
at a farm selected with regard to its history of PCVD.
The farm was constituted of a 1200-sow farrow-to-finish
herd that, in the previous years, had experienced mortal-
ity in the nursery and fattening periods due to PCVD.
This diagnosis was based on clinical signs, gross lesions,
histopathological findings, and presence of PCV2 in
lesions of the lymphoid tissue, all together typical for
PCVD in accordance to Sorden [32]. Seropositivity to
PCV2 in all categories of animals (replacement gilts,
sows, nursery, growing and finishing pigs) was
demonstrated by enzyme-linked immune sorbent assay
(ELISA). Since the occurrence of the disease, the piglets
have been vaccinated at three weeks of age, whereas gilts
and sows were vaccinated at each mating. At the time of
start of the study no clinical signs of PCV2-SD (PCV2-
systemic disease; [28]) were noted. Diagnostic investiga-
tions performed on dead pigs older than 15 weeks of age
demonstrated no PCV2-specific lesions in the lymphoid
tissue. Instead very low titres of the virus determined by
PCR were suggestive for PCV2 subclinical infection in
several pigs (PCV2-SI).
The involvement of Porcine reproductive and respira-
tory syndrome virus (PRRSV) in the clinical problems of
the herd was demonstrated by repeated detection of the
virus by PCR in nursery and growing pigs that were suf-
fering from respiratory disease. However, based on diag-
nostics the herd had been classified as “positive - stable”
for PRRS according to Holtkamp and others [13]. The
presence of the most common secondary bacteria
(Streptococcus spp., Pasteurella multocida) was con-
firmed in animals also tested infected by PRRSV. The
farm was seronegative for Aujeszky’s disease virus (ADV)
and Actinobacillus pleuropneumoniae and seropositive
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for Mycoplasma hyopneumoniae. Sows were vaccinated
against ADV (three times per year), Porcine parvovirus,
Erysipelothrix rhusiopathiae (both at mid-lactation)
and Swine influenza virus (SIV). Piglets were vacci-
nated against M. hyopneumoniae once at one week of
age and ADV according to the National Control Program
of Italy.
Experimental design
This study was a double-blind, randomised, controlled
field trial performed in accordance to the principles of
“Good Clinical Practice” with the consent of animals’
owner and the protocol had been previously evaluated
and approved by the Ethical Committee for Animal Ex-
perimentation of the University of Parma (23/12). The
work has been carried out over three subsequent pro-
duction cycles (replicates). At the beginning, 46 com-
mercial hybrid gilts at 230 to 260 days of age, were
included at their first mating. Replacement gilts were
produced into the farm. They were individually identi-
fied by numbered ear tagging and a blood sample of
approx. 10 mL was obtained by puncture of the Vena
jugularis externa from each animal. Subsequently the
gilts were vaccinated with one dose (2 mL) of a commer-
cial PCV2a-based subunit vaccine (Porcilis® PCV, MSD
Animal Health, Boxmeer, The Netherlands) via intra-
muscular injection in the neck (off-label use). At day
113 of the first, second and third gestation period, these
animals were bled; i.e. two days prior to expected far-
rowing date. The sows were re-vaccinated against PCV2
at the same day of subsequent mating after their piglets
had been weaned. The day of inclusion of suckling pigs
was at their weaning (D -1). On this day, suckling pigs
of each farrowing (first, second and third parity) were
identified, double ear-tagged (both ears) and randomly
assigned to one of the treatment groups. The treatment
groups with 100 animals each differed in the time when
vaccination was applied to the piglets. Namely, animals
in the first group were vaccinated at four weeks of age
(weaning age) (group A), six weeks of age (group B) or
eight weeks of age (group C). One group of piglets was
kept non-vaccinated (group D) as placebo/control. The
animals were assigned to the different groups as they
came to hand sequentially using a randomized block de-
sign (n = 4) across litters. The identification of the sow
and the date of birth of the piglets were recorded.
The piglets were vaccinated with 2 mL of a commercial
PCV2 vaccine (Porcilis PCV®) administered intramuscu-
larly according to the manufacturer’s recommendations.
The non-vaccinated control pigs received the same
amount of adjuvant (2 mL) by injection in the neck at four
weeks of age. The recording of the clinical signs was per-
formed by a veterinarian, who was blinded regarding the
treatments. At weaning, all piglets under investigation
were moved to the nursery unit and kept commingled in
pens of 25 pigs per pen each, all constructed in a unique
barn. Upon each accommodation change, pigs were com-
mingled according to usual farm procedures. Treatments,
housing, husbandry and feeding were in accordance to the
European Union Guidelines on Animal Husbandry and
were identical for all experimental groups.
During the first week post-vaccination, pigs were mon-
itored daily for side reactions. At weaning (four weeks of
age) and at vaccination (four, six or eight weeks of age),
blood samples were collected from 20 piglets per treat-
ment group. These piglets were identified by their num-
ber and a differently coloured ear tag. Further sets of
blood samples were then taken every four weeks until
slaughter (eight [group A only]), 12, 16, 20, 24, 28 and
32 weeks of age in groups A and C, and 10, 14, 18, 22,
26, 30 and 34 in group B). The 20 pigs of the control
group were blood sampled four weeks after they had re-
ceived only the adjuvant (at the time of weaning) and
then on a two week interval until slaughter (10, 12, 14,
16, 18, 20, 22, 24, 26, 28, 30, 32 and 34 weeks of age).
The same procedures were applied in all three replicates
(litters).
Clinical signs (morbidity) and mortality recording
The individual treatment of every pig was recorded on a
daily basis and considered as a parameter for the measure-
ment of morbidity. Dead pigs or those that had to be eu-
thanized for reasons of animal welfare were recorded and
immediately submitted to pathological investigations.
Body weight and average daily weight gain (ADWG)
Individual body weights of the pigs enrolled in the study
were measured at inclusion, at 12 and at 24 weeks of
age. The ADWG was calculated based on the daily
weight gain of all the animals being alive at the end of
each weighing period.
Gross pathology and histopathology
All pigs that died spontaneously and those needing eu-
thanasia underwent gross pathological examination and
histopathology within 24 h after death. Samples from in-
guinal, mesenteric and mediastinic lymph nodes were re-
moved and fixed in 10 % buffered formalin. For routine
histopathology, 5-μm thick sections of the lymph nodes
were stained with haematoxylin-eosin and examined for
lesions compatible with PCV2-SD. The diagnosis of
PCV2-SD was concluded, when all the three criteria for
the disease were present [28] including moderate-to-
high amounts of PCV2 in the lesions determined by
quantitative real-time PCR (qPCR) as described by
Olvera and others [21].
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DNA extraction and qPCR to detect PCV2 nucleic acid in
tissues and serum samples
In order to detect and to quantify the viral DNA by
qPCR, DNA was firstly extracted from 200 μL of serum
and 200 μL of 1:10 PBS homogenate of lymph node
tissue, by using TRIzol LS (Invitrogen–San Diego, CA-
USA) following the manufacturer’s instructions. The
DNA obtained was suspended in 50 μL of DEPC-treated
water. A qPCR was carried out using primers and probes
according to Olvera and others [21] on a LightCycler 1.5
thermocycler (Roche Diagnostics–Basel, CH). The re-
sults were expressed as number of PCV2 genome copies
per millilitre of serum or gram of tissue.
Serology
Detection of PCV2 antibodies
For the detection of PCV2-specific antibodies, a com-
mercially available indirect enzymatic immunoassay
(INGENZIM CIRCO–INGENASA, Madrid, Spain) was
used according to the manufacturer’s instructions. The
titre of each sample was calculated as follows: titre = 53
(e3.2×) where e is the natural logarithm base and x is the
S/P of the sample (S/P = sample O.D./positive control
O.D.; O.D.: optical density).
Retrospective analysis of the courses of PCV2 antibodies
after grouping the animals according to maternally derived
antibodies at vaccination
The animals of the three replicates taken together were
retrospectively grouped based on the value of the S/P ra-
tio at PCV2 vaccination considering a high S/P value (≥
the median S/P ratio of all piglets at 4 weeks of age) and
a low S/P value (< the median).
Detection of antibodies against other infections
Antibodies against M. hyopneumoniae were evaluated by
a commercially available ELISA kit (Herd Check® M.
hyopneumoniae, IDEXX Laboratories). The presence of
antibodies against the gE glycoprotein of ADV was
measured using a commercially available ELISA kit
(HerdChek® PRV g1 (gE) test kit, IDEXX Laboratories)
according to the manufacturer’s instructions. Another
commercial ELISA kit (CHEKIT-APP-ApxIV ELISA test
kit, IDEXX Laboratories) was used for the detection of
antibodies against A. pleuropneumoniae. Antibodies to
different SIV sub-types (H1N1, H1N2 and H3N2) were
determined by a haemoagglutination inhibition (HI)
assay, using a standard method [2]. The presence of
antibodies to PRRSV were determined using a commer-
cially available ELISA kit (HerdChek® Porcine Repro-
ductive and Respiratory Syndrome Antibody Test Kit,
IDEXX Laboratories, Westbrook, ME, USA) according
to the manufacturer’s instructions.
Quantification of PCV2-specific IFN-γ secreting cells
The frequencies of PCV2-specific IFN-γ secreting cells
(SC) in the peripheral blood of pigs were determined ac-
cording to Martelli and others [15] with minor modifica-
tions. Peripheral blood mononuclear cells (PBMCs) were
isolated by Histopaque-1.077® gradient and plated at 4 ×
105 cells/well in complete RPMI-1640 (cRPMI-1640)
supplemented with 10 % foetal bovine serum (FBS) into
96-well plates (MultiScreen®HTS-IP, Millipore) coated
overnight at 4 °C with 5 μg/mL anti-pig IFN-γ mAb
(P2G10, BD, Biosciences, Franklin lakes, NJ - USA) and
blocked with cRPMI-1640 + 10 % FBS for 2 h at 37 °C.
For the PCV2 antigen recall, an elaborate on the whole
strain (I12/11) at 0.1 multiplicity of infection (MOI) was
used as stimulus, in cRPMI-1640 + 10 % FBS, for 20 h at
37 °C, 5 % CO2. In all samples, >98 % of PBMCs were
viable as confirmed by Trypan blue. Afterwards, plates
were incubated for 1 h at 37 °C with 0.5 μg/mL anti-pig
IFN-γ biotin-labelled mAb (P2C11, BD) and then with
1:750 AP-conjugated anti-biotin mAb in PBS + 0.5 %
BSA. Plates were finally incubated for 7 min with a
BCIP/NBT solution (BioRad, Hercules, CA - USA) and
the reaction was stopped with distilled water. The fre-
quencies of PCV2-specific IFN-γ SC were determined
using an AID® ELISpot Reader (AID® ELISpot Software
v.3.5 - AID). As a positive control, 4 × 105 PBMCs/well
were incubated with PHA (5 μg/mL); as a negative con-
trol, 4 × 105 PBMCs were incubated without antigen
(PCV2 mock stimulus: supernatant of non-PCV2-
infected PK-15 cells). The background values (number of
spots in negative control wells) were subtracted from the
respective counts of the stimulated cells and the im-
mune responses were expressed as number of IFN-γ SC
per million PBMCs (IFN-γ SC/106 PBMCs).
Statistical analysis
All statistical analyses were carried out using the
STATA/IC 12.1 for Windows (64-bit ×86-64; StataCorp
LP, College Station, TX, USA). For all analyses, the indi-
vidual pig was considered as the experimental unit.
Descriptive analysis was performed for all individual
parameters from pigs stratified according to replicate
and group. Outcome of continuous variables (ADWG,
PCV2 ELISA S/P, IFN-γ SC and PCV2 viral loads) were
tested for normality (Shapiro-Wild test) and further ana-
lyzed by either one way ANOVA (normally distributed
data) or Kruskall–Wallis test (non-normally distributed
data). Differences between groups were further evaluated
by pairwise comparisons of marginal linear predictions.
Moreover, piglets were re-grouped according to their
level of MDAs into two groups: ‘Low level of MDA’ (S/P
ratio < median S/P ratio of all piglets at 4 weeks of age)
or ‘High level of MDA’ (S/P ratio ≥median). A chi-
square test was used to evaluate differences between
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groups in mortality, the number of animals with a PCV2
viral load higher than 106 PCV2 copies/mL, and the
number of animals needing an individual treatment. The
correlation between ELISA S/P at the time of vaccin-
ation and four weeks later was tested employing linear
regression analysis. The significance level (α) for all ana-
lyses was set at 0.05.
Results
The results of this field trial are described for each of
the three replicates, namely for pigs from nursery to the
finishing phase and derived from the three consecutive
litters (1st, 2nd and 3rd parity) of vaccinated sows.
Morbidity and mortality
Morbidity in pigs of the three replicates is shown in
Table 1. Among pigs of the first replicate, morbidity was
significantly higher in those of groups C and D (p <
0.05). None of the recorded clinical signs that needed
treatment was associated with or typical for PCVD. In
the second replicate, a high proportion of treatments
was needed in all groups and no statistical difference
was observed. All the individual treatments were applied
in the post-weaning period concomitantly with the oc-
currence of a severe outbreak of PRRSV infection and
associated clinical signs. In the third replicate, morbidity
in group B was significantly lower as compared to the
other groups (p < 0.05). In particular, it is worth men-
tioning that the majority of the individual treatments in
groups A, C and D were needed from 12 weeks of age
until slaughter. Pigs belonging to group D had a very
high percentage of diseased pigs (18 %) concomitantly
with the high proportion of PCV2 viremic animals and
high titres of viral burden (see the paragraph about PCV
viremia) even if overt clinical signs compatible with
PCV2-SD were not observed.
Dead pigs, animals needing euthanasia, and runt non-
marketable pigs (lost pigs) underwent pathological and
virological investigations to be categorised as PCVD and
non-PCVD affected. None of the investigated pigs ful-
filled the diagnostic criteria for PCV2-SD. The mortality
rate in the first replicate was significantly lower in group
B (vaccinated at 6 weeks of age) (p < 0.05) in both of the
considered periods of observation, namely from weaning
to 12 weeks of age and from then to slaughter. In the
second replicate, production cycle mortality was signifi-
cantly lower in group C in the period from weaning to
12 weeks. In contrast, in the fattening period (from
12 weeks to slaughter), groups A and B had less mortal-
ity than other groups. None of the fatality cases fulfilled
the diagnostic criteria of PCVD. In the last replicate, the
mortality was significantly lower in groups B and C until
12 weeks and in group B only from 12 weeks of age to
slaughter. The higher mortality in group D was associ-
ated with PCV2 viremia. Details are reported in the
paragraph regarding PCV2 viremia.
Average Daily Weight Gain (ADWG)
The ADWG is considered a useful parameter for meas-
uring the effect of PCVD both in clinical and in subclin-
ical cases. Table 2 shows the ADWG in vaccinated and
placebo/control animals for the two intervals among the
three different weighing time points. The ADWG of the
four groups was not significantly different in any period
of the three considered replicates.
PCV2 viremia
The course of PCV2 viremia was different in the three
replicates. In the first replicate (litters from gilts, i.e. 1st
parity sows), PCV2 viremia was detected in some pigs of
all groups (from 5 % to 25 %). The viral burden was
always <106 PCV2 genome copies/mL of serum. In
the second replicate (litters from 2nd parity sows),
groups A, C and D had different proportions of
viremic pigs, and the viral burden in vaccinated ani-
mals (groups A and C, but not B) and controls was
Table 1 Morbidity (parenteral injections) and mortality in the four groups under study for each replicate
REPLICATE GROUP
A B C D
MORBIDITY* 1st 6.2a 5.4a 14.7b 18.9b
2nd 22.7a 20.7a 21.3a 22.4a
3rd 10.3a 0b 8.3a 18.2a
MORTALITY* 1st from weaning to 12 weeks of age 3.1a 1.6b 3.1a 3.6a
from 12 weeks to slaughter 3.9a 1.6b 4.7a 3.1a
2nd from weaning to 12 weeks of age 5.3a 4.0a 2.7b 4.3a
from 12 weeks to slaughter 2.7a 2.7a 4.0b 5.4b
3rd from weaning to 12 weeks of age 5.7a 1.9b 2.0b 3.8a
from 12 weeks to slaughter 14.0a 7.7b 18.0a 20.0a
Legend: * proportion of pigs; Different superscript letters indicate statistically significant differences (p < 0.05)
Group A: pigs vaccinated at 4 weeks; group B: pigs vaccinated at 6 weeks; group C: pigs vaccinated at 8 weeks; group D: non-vaccinated placebo/controls
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confirmed to be always <106 PCV2 genome copies/
mL of serum. In the last replicate (litters from 3rd
parity sows), PCV2 viremia was detected in group D
(placebo/control) from 16 weeks of age to the end of
the experiment, and the proportion of viremic ani-
mals ranged from 47 % to 100 %. The high propor-
tion of PCV2 viremia was associated with a viral
burden >106 PCV2 genome copies/mL of serum in
at least one sampling per pig during the whole
period of positivity.
Serology
Serologic response to PCV2 vaccination and infection
The course of serology for PCV2 in the three replicates
is shown in Fig. 1 (a-c). In the first replicate, pigs of
groups B and C had an increase of the S/P ratio after
vaccination, whereas pigs in group A and non-
vaccinated pigs showed a decline during the four weeks
post-vaccination. In the second replicate, no increases of
S/P values were recorded in any group after vaccination.
From 12 weeks of age onwards in both replicates (1 and
2), all vaccinated groups showed significantly higher
values of S/P compared to the controls (group D). The
same course of ELISA antibodies in vaccinated pigs was
observed in the third replicate. In fact, the values of the
S/P ratio in vaccinated animals (all groups) did not in-
crease after vaccination and kept a stable course over
the threshold of positivity. At 16 to 18 weeks of age the
non-vaccinated control pigs (group D) seroconverted
shown by an increase of the average S/P ratio.
Retrospective analysis of the courses of PCV2 antibodies
after grouping animals according to the levels of
maternally derived antibodies at vaccination
The values of the S/P ratio are also presented (Fig. 2).
Animals with high S/P ratios due to MDA demonstrated
an identical decline of PCV2 antibodies. In vaccinated
animals, 4 weeks after vaccination, the decline stopped
and remained in a stable state for the whole duration of
the study. Conversely, in non-vaccinated animals having
high S/P values, the decline was longer reaching values
below the threshold of seropositivity (<0.4) at 12 weeks.
The animals with low S/P values at vaccination showed
no decline of antibodies and a stable course that was not
significantly different compared to the levels in vacci-
nated pigs with high S/P values. In the low S/P value
non-vaccinated group, the levels of antibodies de-
clined promptly, reaching a negative value in 4 weeks.
Similarly to the non-vaccinated group with high S/P
value, the viremic pigs of this group seroconverted
later in their life.
The antibody course in non-vaccinated groups de-
clined and maintained values below the threshold of
seropositivity for the whole duration of the study. In
contrast, vaccination in animals with high S/P values
did not induce seroconversion but only a decline
followed by a stable state. In animals with low S/P
values, the course of antibodies was characterized by
a marked seroconversion and the S/P values shown
for the whole duration of the trial were not different
as compared to those of animals with high S/P values
at vaccination.
A correlation between S/P values at the time of vac-
cination and four weeks later could be confirmed for
pigs in group A and group D (Table 3). In contrast to
this, no correlation were observed when pigs were vacci-
nated with 6 or 8 weeks of age.
Serologic response to other infections
Serologic investigations performed to monitor the most
frequently occurring infections in the herds (PRRSV and
M. hyopneumoniae) found that the prevalence of PRRSV
infection was 100 % at 12-15 weeks of age in all groups
and replicates. Concomitantly, M. hyopneumoniae sero-
conversion was also observed. For the latter antigen,
seroprevalence continued to increase in the subsequent
period in all replicates (data not shown).
Low titres of antibodies (at HI) to SIV were detected
in some samples and were inconclusive. Antibodies to
ADV were not detected in any sample at any time point.
Table 2 Average daily weight gain (ADWG) ± STD in the four groups under study for each replicate
REPLICATE GROUP
A B C D
(100)b (100)b (100)b (100)b
ADWGa 1st from weaning to 12 weeks of age 317 ± 78 303 ± 92 310 ± 69 325 ± 71
from 12 weeks to 24 weeks of age 681 ± 129 649 ± 131 633 ± 98 683 ± 132
2nd from weaning to 12 weeks of age 244 ± 92 308 ± 72 255 ± 83 304 ± 75
from 12 weeks to 24 weeks of age 613 ± 97 683 ± 115 623 ± 125 696 ± 104
3rd from weaning to 12 weeks of age 391 ± 72 410 ± 89 420 ± 91 363 ± 88
from 12 weeks to 24 weeks of age 741 ± 110 740 ± 107 704 ± 124 730 ± 121
aaverage daily weight gain: grams/day; bnumber of pigs at enrolment (first weighing)
Group A: pigs vaccinated at 4 weeks; group B: pigs vaccinated at 6 weeks; group C: pigs vaccinated at 8 weeks; group D: non-vaccinated placebo/controls
Martelli et al. BMC Veterinary Research  (2016) 12:77 Page 6 of 12
Fig. 1 Course of the serologic response to PCV2 (Mean ± STD anti-PCV2 ELISA antibodies) in the four groups under study (PCV2-vaccinated and
unvaccinated) for each consecutive replicate (a, b, c). Group A: pigs vaccinated at 4 weeks; group B: pigs vaccinated at 6 weeks; group C: pigs
vaccinated at 8 weeks; group D: non-vaccinated placebo/controls
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Cell-mediated immune response to PCV2 vaccination and
infection
In the first and second replicates, in all vaccinated
groups, an increase of the PCV2-specific IFN-γ SC levels
was observed after vaccination regardless of the vaccin-
ation timing (4, 6 or 8 weeks of age). For the whole dur-
ation of the study, the frequencies of IFN-γ SC remained
stable with some non-significant variations. Control
animals (group D) concomitantly showed an increase
with PCV2 infection in some animals. Notably, in the
second replicate, the values of IFN-γ SC after vaccin-
ation were lower as compared to those recorded in the
first replicate (Fig. 3a-c).
In the third replicate, the increase of IFN-γ SC post-
vaccination was numerically higher in comparison with
the previous replicates. Moreover, the IFN-γ SC main-
tained high levels during the whole period of infection
concomitantly with the onset and increase of the re-
sponse in the control group (group D) between 20-22
and 34 weeks of age.
Discussion and conclusions
The present study is aimed at assessing the efficacy of
and the immunological response to a commercial PCV2a
sub-type based subunit vaccine when administered at
different ages (4, 6 and 8 weeks of age) in pigs with
theoretically higher and more homogeneous levels of
maternally derived immunity obtained by repeated vacci-
nations in the population of the matching mothers (gilts
and sows). Thus, this purpose could allow defining and
evaluating a delayed vaccination scheme of piglets
(vaccination at 6 or 8 weeks of age) in respect to the
conventional timing (3 weeks of age or earlier) in order
to optimize the vaccination scheme. To evaluate the ef-
fects of vaccination, clinical, pathological and virological
outcomes as well as some aspects of the humoral and
cell-mediated immune response towards PCV2 were
studied. Under the conditions of this study, the onset of
the clinical signs related to PCV2-SD did not occur in
the first two replicates as demonstrated by the relatively
low PCV2 natural challenge in the blood of vaccinated
and particularly of non-vaccinated and more susceptible
Fig. 2 Course of the serologic response to PCV2 (Mean ± STD anti-PCV2 ELISA antibodies) according to the levels of maternal derived antibodies
(MDA) at vaccination and PCV2 infection (viremia) occurred at 20 weeks of age. Overall, the animals of the 3 replicates were divided based on a
low (≤0.9) or high (≥1.2) S/P value at 4 weeks of age when vaccinated animals were inoculated with the vaccine (“HIGH S/P vac” and “LOW S/P
vac” groups) while unvaccinated animals were inoculated with the adjuvant alone (“HIGH S/P NV” and “LOW S/P NV” groups)
Table 3 Correlation of PCV2-specific antibodies in piglets at the
time of vaccination and 4 weeks later in the four groups under
study for each replicate
Regression coefficient Lower CI Upper CI p-value
Group A 0.521 0.218 0.825 <0.001
Group B −0.088 −0.474 0.299 0.651
Group C 0.038 −0.215 0.290 0.766
Group D 0.777 0.500 1.055 <0.001
Group A: pigs vaccinated at 4 weeks; group B: pigs vaccinated at 6 weeks;
group C: pigs vaccinated at 8 weeks; group D:
non-vaccinated placebo/controls
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Fig. 3 Course of PCV2-specific IFN-γ SC number (Mean ± STD) in the four groups under study (PCV2-vaccinated and unvaccinated) for each
consecutive replicate (a, b, c). Group A: pigs vaccinated at 4 weeks; group B: pigs vaccinated at 6 weeks; group C: pigs vaccinated at 8 weeks;
group D: non-vaccinated placebo/controls
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pigs. In the third replicate, PCV2 infection and morbid-
ity were detected from 16 weeks of age to the end of the
observation period in controls in conjunction with a
more intense PCV2 natural challenge.
The present data clearly indicates that vaccination
against PCV2 at different ages induces a statistically sig-
nificant reduction of the proportion of viremic animals
and also of the viral load in the blood compared to pla-
cebo/controls (p < 0.05).
Vaccination with a single dose of the test vaccine ad-
ministered intramuscularly at 3 weeks of age consistently
reduced the clinical signs attributed to PCVD as well as
mortality and PCV2 viral load and viremia [7, 15, 16].
More recently, the effect of sow and piglet vaccination
under the same field conditions was proven [9].
Overall in the three replicates, it was confirmed that
mortality was numerically reduced in vaccinated animals
when PCV2 infection occurred and, under the condi-
tions of this study, statistically significant differences
were observed in animals vaccinated at 6 weeks of
age. To measure morbidity, the number of individual
treatments in unvaccinated and vaccinated animals
was recorded throughout the study. After intense
PCV2 natural challenge, morbidity was significantly
higher in the placebo/control group compared to all
vaccinated animals.
Average daily weight gain was also evaluated as an effi-
cacy parameter for the vaccination schedule under inves-
tigation. Both before the onset of PCV2 viremia and
associated disease (from 4 to 12 weeks of age), and from
12 to 24 weeks (the period when PCV2 viremia occurred
in the third replicate), the ADWG was not positively af-
fected in vaccinated animals. This result is not in ac-
cordance with previous studies [4, 12, 14, 15, 27]
supporting a positive effect of vaccination on this par-
ameter. The inability to detect any influence of PCV2
viremia on the productive performance of vaccinated an-
imals compared to controls can be attributed to the early
measurement of body weight (24 weeks of age) in re-
spect to the occurrence of viremia detected until the end
of the study. Thus control animals experienced the ef-
fects of PCV2 viremia after the last weighing. These re-
sults highlight the fact that PCV2 natural challenge can
occur late in the fattening period and, particularly, that
viremia can last very long until the slaughter time.
The improved clinical parameters (morbidity and mor-
tality) are associated with a significant reduction in the
proportion of infected pigs and in the viral load in the
blood. Particularly, in the third replicate, when PCV2
natural challenge overtly occurred (from 16 weeks of age
onward), a high number of placebo/control pigs had
high viral loads in serum (>106 DNA copies/mL),
whereas in vaccinated pigs the duration of viremia and
the viral load were markedly lower (A and C) or
neglectable (group B). It is remarkable that pigs vacci-
nated at 6 weeks of age (group B) never became PCR-
positive for PCV2 in all replicates. It is also notable that,
in an almost one year and half time period of observa-
tion in the field conditions of this study, PCV2 infection
was undetectable for a certain time period (two repli-
cates) and suddenly re-appeared without any evident
and expected reason.
All tested animals were PCV2 negative by PCR at the
time of vaccination so that the antibody titres detected
were most likely of maternal origin also in pigs vacci-
nated at 8 weeks of age. Overall, the S/P ratio in piglets
at 4 weeks of age increased in the three subsequent
replicates as a consequence of the effect of repeated vac-
cination of the corresponding dams at mating. Thus, in
the 1st replicate, even if the S/P ratios were the lowest
within the three considered replicate, no seroconversion
was measured overall in piglets vaccinated at 4 weeks of
age as a consequence of some interference of the MDA
passively transferred by colostrum on seroconvertion by
vaccination. This result is in accordance with a previous
study [15]. Conversely, seroconversion could be mea-
sured in animals vaccinated at 6 and 8 weeks of age
(group B and C, respectively) as a direct consequence of
the decline of MDA occurring within 2-4 weeks. In the
2nd and 3rd replicates this reduction of MDA was de-
layed because of the higher level of the S/P ratio at
4 weeks of age. However, upon vaccination, even when
seroconversion did not occur, the S/P ratios remained
above the threshold of positivity (S/P >0.4) throughout
the study. On the other hand, the placebo/controls had a
continuous decline of MDA reaching negative values (S/
P <0.4) at 10 weeks of age. The retrospective analysis of
the course of PCV2 antibodies after grouping animals
according to maternally derived antibody levels mea-
sured as S/P ratios at vaccination supports that animals
with high values of S/P ratio do not seroconvert whereas
vaccinated animals with low S/P values do. Interestingly,
the course of the S/P ratios for the whole duration of
the study maintained at stable levels with no differences
in the absolute values comparing the two groups (high
S/P vs. low S/P). Moreover, non-vaccinated animals,
both with high and low MDA, experience a decline
reaching negative values during the second month of
life. Non-vaccinated animals grouped according to the
occurrence of PCV2 natural challenge seroconvert soon
after viremia. Vaccinated animals either seroconverting
because of low levels of MDA or not due to high MDA,
maintain stable and efficient, protective values of anti-
bodies for the whole production cycle even when PCV2
natural exposure occurs relatively late in their life (from
16 weeks onward). Thus, these results make clear that
the degree of protection is not higher in animals with
low S/P values at vaccination compared to those with
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high values. It has been shown that in Group A and D
antibody concentration at the time of vaccination signifi-
cantly correlates with the antibody concentration four
weeks later, which was always lower than the value be-
fore. This underlines the hypothesis that high concentra-
tion of MDA prevent seroconversion in vaccinated pigs
(Group A), whereas low to medium concentration
(Group B and C, being two and four weeks, respectively,
older at the time of vaccination) does not interfere with
the humoral immune response. The latter assumption of
no correlation between these levels of MDA and the in-
dividual response to vaccination is confirmed by the ab-
sence of any significant correlation of S/P values in
Group B and C during four weeks following vaccination.
Some studies investigated the influence of age on the
efficacy of one-dose PCV2 vaccination in piglets with
high levels of maternally derived antibodies. A recent
paper studied the efficacy of vaccination at one and
three weeks of age under field conditions [11]. Simi-
larly to this study, we detected mean values of MDA
in piglets that increased in parallel with the parity of
the sows [17].
A previous study [15] demonstrated that PCV2 vac-
cine efficacy is also sustained by the development of the
cellular immune response and this is confirmed by the
increased levels of IFN-γ SC in pigs soon after vaccin-
ation, supporting the capacity of the PCV2 subunit
vaccine to induce cellular immunity which response is
not negatively influenced by the presence of high MDA.
The age-dependent induction of the cellular response
and the influence of the MDA in vaccinated animals are
important features to evaluate since different outcomes
(extent and duration of the recalled immunity) can be
observed in different species and in relation to the chal-
lenge conditions [1, 3, 24, 25]. The data of the present
paper confirm that the cell-mediated immunity to PCV2
measured as IFN-γ SC was induced within 4 weeks post-
vaccination in all replicates and all vaccinated groups.
The levels of IFN-γ SC are maintained stable throughout
the study (34 weeks of age) and are at the highest levels
during the period of late infection that occurred in the
third replicate.
In conclusion, the present study demonstrates the
beneficial effect of vaccination with a single dose of a
PCV2 Cap-based vaccine against PCVD under field con-
ditions even in the presence of high levels of MDA at
the time of vaccination, particularly when the experi-
mental animals (all groups) were exposed to a “robust”
PCV2 natural infection.
The effects of vaccination at different ages are strictly
associated with virological and clinical protection as a
result of the immunogenicity of the tested vaccine mea-
sured as activation of both the humoral and cellular im-
mune response. This trial demonstrates that even in a
condition of high levels of MDA, piglets vaccination at
4, 6 or 8 weeks of age confer a protective immune re-
sponse characterized by cellular immunity and a stable
and long-lasting (until 34 weeks of age) antibody re-
sponse. However, in the conditions of this study, the
combination of vaccination in sows at mating and in
piglets at 6 weeks of age was more effective for control-
ling PCV2 natural infection, than other treatment sche-
mas, thus sustaining that some interference of MDA
with the induction of an efficient immune response
could be considered. These evidences are in agreement
with the conclusion of a research based on experimen-
tally PCV2 infected pigs with or without MDA [20]. In
conclusion, optimal vaccination strategy needs to bal-
ance the levels of passive immunity, the management
practices and timing of infection.
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